SecBot SecBot

MREO

Mereo BioPharma Group plc
Nasdaq· Pharmaceutical Preparations· Inc. X0· CIK 0001719714 Biotech & Drug Discovery
$0.2750 −0.01 (−2.48%)
Oct 26 4:00 PM ET · prev $0.2820
Market cap
$45.9M
Nano cap
Consensus
Buy
77% Buy or better · 13 analysts
Median target
🔒 Subscribers only
Next earnings
Nov 9
in 13 days · EPS est. −$0.01
1 year
−86.2%
from $2.00 · Oct 27
30 days
−25.7%
from $0.3700
52-week range
$0.2370–2.31
−88% from high · low May 6
Avg volume 20D
1.08M
Sep 30 spike 3.07M
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 1 bearish · 1 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/4 ·Next Earnings date, Nov 9, 2026
Strongest BEARISH Mereo BioPharma received a second Nasdaq notice granting an additional 180-day compliance period (until…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 4 added (0 new), 3 trimmed or exited.

  • AnalystsBULLISH

    10 of 13 rate it Buy or better.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.007 → −$0.011 over 90 days.

  • TrendDOWNTREND

    10% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
JANE STREET GROUP, LLCDOUBLED774,944$246.2K
MARSHALL WACE, LLPTRIM179,884$57.6K
GROUP ONE TRADING LLCTRIM167,515$53.2K
BlackRock, Inc.NEAR_EXIT69,678$22.1K
JPMORGAN CHASE & CODOUBLED58,531$19.4K
RHUMBLINE ADVISERSADD26,784$8.5K
Arax Advisory PartnersADD5,819$1.8K
BANK OF AMERICA CORP /DE/DOUBLED8,195,287$2.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 77% rate it Buy or better
Strong Buy5Buy5Hold2Sell1Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Aug 19, 2026JP Morgan
DOWNGRADE
DOWNGRADEUnderweight
Aug 11, 2026BTIG
REITERATE
REITERATEBuy
Aug 11, 2026Needham
REITERATE
REITERATEBuy
May 12, 2026BTIG
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Feb 26, 2026
Shames Daniel
Director
AWARD96,163 sh
Feb 26, 2026
WYZGA MICHAEL S
Director
AWARD66,000 sh
Feb 26, 2026
Bender Jeremy
Director
AWARD66,000 sh
Feb 26, 2026
PAKIANATHAN DEEPIKA
Director
AWARD66,000 sh
Feb 26, 2026
Jenkins Annalisa
Director
AWARD66,000 sh
Feb 26, 2026
Jenkins Annalisa
Director
AWARD106,848 sh
Feb 26, 2026
Jacquet Pierre
Director
AWARD106,848 sh
Feb 26, 2026
Bender Jeremy
Director
AWARD117,533 sh

Earnings setup

Estimates
Nov 9
reports in 13 days
−$0.01
EPS estimate, this quarter
−57%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.01-$0.03–-$0.01+0.0%$0.00
Next Q-$0.01-$0.03–-$0.01+0.0%$12.3K
Current FY-$0.04-$0.13–-$0.02+0.0%$0.00
Next FY-$0.02-$0.05–$0.02+0.0%$14.4M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Short interest report
🔒 Fresh data, subscribers only
Aug 19, 2026 SEC
Mereo BioPharma received a second Nasdaq notice granting an additional 180-day compliance period (until February 16…
8-K — Impact 7/10
Aug 11, 2026 SEC
Mereo BioPharma reported Q2 2026 results with a net loss of $7.0M, improved from a $14.6M loss in Q2 2025, driven by…
8-K — Impact 6/10
Aug 11, 2026 SEC
Mereo BioPharma reported Q2 2026 results with zero revenue and a net loss of $7.0M, in line with consensus EPS of…
PRESS-RELEASE — Impact 4/10
Jun 30, 2026 Inst.
JANE STREET GROUP, LLC — DOUBLED
774,944 shares ($246.2K)
Jun 30, 2026 Inst.
MARSHALL WACE, LLP — TRIM
179,884 shares ($57.6K)
Mar 19, 2026 Press
Mereo BioPharma reported its 2025 financial results, showing a narrower net loss of $41.9 million compared to $43.3…
Impact 6/10
Feb 26, 2026 Insider
Shames Daniel was granted 96,163 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
MREO Q3 2026 Earnings Scheduled — 2026-11-09
Recent
Oct 15, 2026
Short interest
🔒 Fresh data, subscribers only
Aug 14, 2026
Short interest
Short Interest: MREO up 26% to 4.3M shares
Settlement 2026-08-14 | Days to cover: 1.00 | ≈2.78% of shares outstanding (est.)
Aug 11, 2026
Earnings
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin…
Aug 10, 2026
Earnings date
MREO Q2 2026 Earnings Scheduled — 2026-08-10
Jul 15, 2026
Short interest
Short Interest: MREO down 40% to 3.5M shares
Settlement 2026-07-15 | Days to cover: 3.23 | ≈2.28% of shares outstanding (est.)

SecBot reports

6 filings · 1 press release · 1 bullish · 2 bearish · 1 mixed · 2 neutral
All MREO filing & press-release reports (7)